Delaware
|
001-32325
|
13-3894575
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
of
incorporation or organization)
|
420
Lexington Avenue, Suite 1609
|
|
|
|
New
York, New York
10170
|
|
|
(Address
of principal executive offices)
|
o
|
Written
communication pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR
240.13e-4(c))
|
Item 1.01 | Entry into a Material Definitive Agreement. |
Item 3.02 | Unregistered Sales of Equity Securities. |
Item 9.01 | Financial Statements and Exhibits. | ||
(c)
|
Exhibits | ||
4.1 | Form of Warrant to purchase Common Stock issued in connection with the sale of Common Stock. | ||
4.2 | Form of Warrant to purchase Common Stock issued to certain selling agents in connection with the sale of Common Stock. | ||
10.1 |
Securities
Purchase Agreement dated February 3, 2006 between Callisto
Pharmaceuticals, Inc. and the investors listed on Exhibit A
thereto.
|
||
99.1 | Press Release dated February 3, 2006. |
CALLISTO
PHARMACEUTICALS, INC.
|
||
|
|
|
By: | /s/ Gary S. Jacob | |
|
||
Gary
S. Jacob, Ph.D.
Chief
Executive Officer
|